Parenteral iron has emerged as an important tool in anemia management in CKD, either by itself or when combined with Epo.[34] However, our findings suggest that there could be a downside to an indiscriminate administration of IV iron, as it probably contributes to the inflammatory state. The gene discussed is EPO; the disease is anemia (phenotype).